Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 29;16:297–308. doi: 10.2147/OTT.S263829

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Wijnen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Overview of study groups assessing the effect of gemtuzumab ozogamicin during different time periods in treatment of pediatric acute myeloid leukemia.

Notes: The number of patients concerns pediatric patients who were randomized to either receive GO or not. *Patients 0–14 years. **Initially, the combination of ADE + GO was used only in patients with >25% bone marrow blasts after induction 1. Patients with an MRD level >0.1% after induction 2 were given GO at a dose of 6 mg/m² as induction 3. The protocol was amended in 2005 to give ADE + GO as induction 2 to patients with an MRD level >1% after induction 1, and thereby eliminate the use of single-agent GO as induction 3. ***As post-consolidation therapy, repeated after 3 weeks.

Abbreviations: ADE, Ara-C + daunorubicin + etoposide; AML, acute myeloid leukemia; COG, Children’s Oncology Group; GO, gemtuzumab ozogamicin; MRC, Medical Research Council; NOPHO, Nordic Society of Paediatric Haematology and Oncology.